Wasatch Advisors LP Makes New Investment in Immatics (NASDAQ:IMTX)

Wasatch Advisors LP bought a new position in shares of Immatics (NASDAQ:IMTX) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 730,394 shares of the company’s stock, valued at approximately $7,676,000. Wasatch Advisors LP owned 0.86% of Immatics as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Exchange Traded Concepts LLC grew its holdings in Immatics by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 11,501 shares of the company’s stock worth $121,000 after acquiring an additional 2,916 shares during the period. ADAR1 Capital Management LLC acquired a new stake in Immatics during the 4th quarter worth $232,000. Trexquant Investment LP grew its holdings in Immatics by 4.2% during the 4th quarter. Trexquant Investment LP now owns 44,773 shares of the company’s stock worth $471,000 after acquiring an additional 1,801 shares during the period. Jump Financial LLC grew its holdings in Immatics by 19.8% during the 4th quarter. Jump Financial LLC now owns 48,484 shares of the company’s stock worth $511,000 after acquiring an additional 8,014 shares during the period. Finally, Superstring Capital Management LP acquired a new stake in Immatics during the 4th quarter worth $834,000. Institutional investors and hedge funds own 64.41% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Mizuho boosted their price target on shares of Immatics from $14.00 to $16.00 and gave the company a “buy” rating in a report on Thursday, May 16th.

Immatics Trading Up 0.2 %

Shares of IMTX stock traded up $0.02 on Tuesday, hitting $12.02. The stock had a trading volume of 339,608 shares, compared to its average volume of 520,243. Immatics has a twelve month low of $7.15 and a twelve month high of $13.77. The firm has a market cap of $1.02 billion, a P/E ratio of -11.34 and a beta of 0.75. The company has a fifty day moving average price of $11.57 and a two-hundred day moving average price of $11.38.

Immatics (NASDAQ:IMTX) last announced its quarterly earnings results on Tuesday, May 14th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.74) by $0.70. Immatics had a negative net margin of 107.80% and a negative return on equity of 29.36%. The company had revenue of $32.87 million during the quarter, compared to analyst estimates of $17.76 million. On average, analysts expect that Immatics will post -1.26 earnings per share for the current year.

Immatics Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.